Prospective Evaluation of Taste Function In Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation
| Status: | Recruiting |
|---|---|
| Conditions: | Blood Cancer, Hematology, Hematology |
| Therapuetic Areas: | Hematology, Oncology |
| Healthy: | No |
| Age Range: | 21 - Any |
| Updated: | 4/4/2019 |
| Start Date: | August 28, 2017 |
| End Date: | August 28, 2019 |
| Contact: | Sergio Giralt, MD |
| Email: | GiraltS@mskcc.org |
| Phone: | 212-639-3859 |
Prospective Evaluation of Gustatory Function (Taste) In Patients Undergoing Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
The purpose of this study is to study taste disturbances on patients with myeloma who
received high dose melphalan.
received high dose melphalan.
Inclusion Criteria:
- Age 21 or above with diagnosis of multiple myeloma (myeloma is almost unheard of in
patients less than 21 years of age).
- Scheduled to receive conditioning chemotherapy with melphalan followed by upfront or
salvage autologous peripheral blood hematopoietic stem cell transplantation
- English or Spanish speaking
- Calculated creatinine clearance > 40 mL/min
Exclusion Criteria:
- Prior head and neck radiation.
- Severe periodontal infection. Poor oral hygiene and dentition as determined by pre HCT
dental assessment.
- Pregnancy
- Patients with pre-existing moderate-severe dysgeusia
We found this trial at
1
site
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Phone: 212-639-3859
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
